Sign up for our newsletter

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in quick-to-read digest. This month, we explore: Treatment durability of PRP and HA The growing importance of platelet dose when assessing outcomes One-year outcomes following the GPS III PRP system Orthobiologics serving as adjuncts during cartilage-preservation surgery Preclinical evidence supporting Prolotherapy + HA combination for OA Let's di

MD Biologix earns a place on The Globe and Mail's eighth annual ranking for the first time TORONTO, ONTARIO — MD Biologix has been named one of Canada's Top Growing Companies by The Globe and Mail’s Report on Business magazine, earning a place on the 2026 ranking for the first time in the company's history. The company ranks No. 38 in the Health Care & Wellness category, with three-year revenue growth of 51%. MD Biologix is a family-owned Canadian distributor of regenerative

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in quick-to-read digest. This month, we explore: Comparing the clinical efficacy of PRP and Hyaluronic acid in knee OA PRP + HA combination therapy showing improved pain and function up to 24 post injection The effects of a high-molecular weight and linear HA on synovial fluid and joint environment Comparing year-long outcomes outcomes with leuko

Platelet dose is the driver of clinical outcomes in PRP: the absolute number of platelets delivered to the tissue, not the multipliers on label. Volume matters because how much blood you draw, ultimately decides how much material is being processed and caps your dosing. In contrast, how much you inject dictates whether that same dose is adequately saturating the tissue you’re injecting. Dose is the variable that tracks with outcome Back when PRP first came onto the scene,

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in a quick-to-read digest. This month, we explore: A Level I network meta-analysis of 24 RCTs concluding no orthobiologic beats HA by a clinically meaningful margin 3,667 knee OA patients, where income, employment and distance to care predicted who received PRP 23 international experts agreeing on 10 post-PRP rehabilitation recommendations High mo

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in a quick-to-read digest. This month, we explore: A network meta-analysis of 18 RCTs asking which PRP add-on actually earns its place: HA, stem cells, or ozone A real-world head-to-head where a non-crosslinked, hybrid-MW HA held its own in two injections against three of PRP A meta-analysis of 16 trials confirming that PRP+HA pulls ahead of PRP a

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in a quick-to-read digest. This month, we explore: A head-to-head RCT on whether ultra-high molecular weight and cross-linking buy greater pain relief than high MW HA or saline in knee OA A fragility index–based meta-analysis on PRP and return to sport after acute muscle injury, including the platelet doses behind the systems used A practical over